The tumor profiling assay will have similar chemistry and analytics to TruSight Oncology 500 (TSO 500). The IVD test is now undergoing regulatory review and is set to be launched in both the U.S. and Europe later this year . . .
Home Biomarkers Circulating Tumor Cell Illumina Launching Pan-Cancer IVD Test, Cloud-Based Bioinformatics Platform
- Biomarkers
- Circulating Tumor Cell
- Translational Medicine
- Cancer
- Information Management
- Bioinformatics
- OMICs
- Sequencing
- Next-Generation Sequencing
- GEN Edge
- Illumina
- Molecular Diagnostics/In vitro Diagnostics
Illumina Launching Pan-Cancer IVD Test, Cloud-Based Bioinformatics Platform
CEO Francis deSouza says tech breakthroughs will enable the long-discussed $100 genome
Illumina has revealed plans to step up its cancer detection efforts by launching a new in vitro diagnostic (IVD) test and bolstering its oncology-focused companion diagnostic (CDx) collaborations—as well as plans to launch a new cloud-based bioinformatics data platform. [Illumina]
